Sign up Australia
Proactive Investors - Run By Investors For Investors

Faron Pharma to provide drug compassionate use of drug; data monitors green light study as it moves into its final few months

The study, codenamed INTEREST, should be wrapped up in the fourth-quarter
Clinical Trial
Faron plans to treat 300 ARDS patients with Traumakine

Faron Pharmaceuticals Ltd (LON:FARN) said it is planning to provide its lead drug on a compassionate use basis once its phase III clinical trial has concluded.

The study, codenamed INTEREST, should be wrapped up in the fourth-quarter.

It was set up to assess the efficacy of Traumakine in treating acute respiratory distress syndrome (ARDS).

Faron said in its latest release that the independent data monitoring committee (IMDC) overseeing the clinical investigation has said the trial should continue unchanged.

Unment medical need

This is consistent with its four previous recommendations.

Faron plans to treat 300 ARDS patients with Traumakine, which performed well in an earlier phase II clinical study.

ARDS is severe lung condition that often results from pneumonia and has mortality rate of 30-45% with 300,000 cases annually in Europe and the US.

"We are very pleased to receive the IDMC's recommendation that the INTEREST study should continue as planned,” said Faron chief executive, Dr Markku Jalkanen.

“The trial is now moving into its final stages and we look forward to closing recruitment during the fourth quarter of 2017.”

'Cleva'  approach

Faron’s pipeline also includes a Clevegen, a pre-clinical drug designed uses the body’s own immune system to tackle cancer.

As the name suggests it does something new and clever that marks out from all the other immuno-oncology treatments coming out of the lab and into early trials.

Consisting of anti-Clever-1 antibody it converts the immune environment around a tumour from being suppressive to immune stimulating.

WATCH: Markku Jalkanen 'excited' to be advancing Clevegen

View full FARN profile View Profile

Faron Pharmaceuticals Ltd Timeline

September 12 2018

Related Articles

Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.
People working in a laboratory
May 02 2018
The benefits of Admedus' proprietary ADAPT technology and products are now scientifically proven beyond doubt.
June 05 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use